Authors: Centeno, C., Al-Sayegh, H., Freeman, M., & Centeno, C.
Published: 2015
Conclusion: Based on this small case series, autologous bone marrow concentrate shows promise in the treatment of grade 1, 2, and possibly grade 3 ACL tears without retraction. Further investigation using a controlled study design is warranted.
Authors: Wells, K., BA, Klein, M., MD, Hurwitz, N., BS, Santiago, K., BA, Cheng, J., PhD, Abutalib, Z., MHS, . . . Lutz, G., MD.
Published: 2020
Conclusion: The cellular content of BMA samples varied widely between patients and was lower than the anticipated yield reported by the device's manufacturer. However, intra‐articular BMA injections for knee OA in a small pilot cohort appeared to be safe with potential therapeutic value. Larger, prospective, double‐blinded studies are warranted.
Conclusion: Treatment of cartilage lesions with BMAC and Hyalofast is a viable and effective option that is mainly affected by lesion size and number and not by age. In particular, it allows to address the >45 years population with functional outcomes that are comparable to younger patients at fnal follow-up.
Authors: Emadedin, M., Narges, L., Maede, L. G., Hosseini, S., Baharvand, H., & Aghdami, N.
Published: 2018
Conclusion: This randomized, triple-blind, placebo-controlled RCT demonstrated the safety and efficacy of a single intra-articular implantation of 40×10 autologous MSCs in patients with knee OA. Intra-articular implantation of MSCs provided significant and clinically relevant pain relief over 6 months versus placebo and could be considered a promising novel treatment for knee OA. We propose that further investigations should be conducted over an extended assessment period and with a larger cohort.
Conclusion: This study shows that injecting the knee joint and tibial metaphysis has safety and efficacy. The improvement in VAS and LEFS was statistically significant (p<0.001). The average patient improved 59% in VAS and 47% in LEFS. MRI scans showed resolution of the tibial metaphyseal hyperemia in 10/12 patients. No patient had knee surgery during the study. No patient was made worse from the biologic procedure. These results indicate much of the pain of knee OA may be from inflamed metaphyseal bone and not cartilage degradation. It may be appropriate for a patient with OA to have a knee joint and tibial metaphyseal injection of autogenous BMC prior to consideration of total knee arthroplasty.
Authors: Chahla, J., Cinque, M. E., Schon, J. M., Liechti, D. J., Matheny, L. M., Laprade, R. F., & Clanton, T. O.
Published: 2016
Conclusion: This review denotes that there exists an overwhelming paucity of long-term data and high-level evidence supporting BMAC for the treatment of chondral defects. Nonetheless, the evidence available showed varying degrees of beneficial results of BMAC for the treatment of ankle cartilage defects. The limited literature presented in this review demonstrates the need for more advanced, comparative studies to further investigate the efficacy, safety and techniques for BMAC in the treatment of OLTs. The authors recommend that BMAC therapy should be performed with careful consideration until the application and target population for this treatment are established.
Authors: Houdek, M. T., Wyles, C. C., Collins, M. S., Howe, B. M., Terzic, A., Behfar, A., & Sierra, R. J.
Published: 2018
Conclusion: Core hip decompression with injection of concentrated bone marrow plus PRP improved pain and function; > 90% of hips in this series were without collapse at a minimum of 2 years. In this preliminary study, successful results were seen when nucleated cell count was high and modified Kerboul grade was low. Further randomized studies are needed to determine this procedure’s efficacy versus core decompression or nonoperative treatment alone.
Authors: Tomaru, Y., Yoshioka, T., Sugaya, H., Kumagai, H., Hyodo, K., Aoto, K., … Mishima, H.
Published: 2019
Conclusion: On the basis of our long-term findings, the minimally invasive and feasible CABMAT therapy can be utilized as one of a joint-preserving treatment for ONFH.
Authors: Pettine, K. A., Suzuki, R. K., Sand, T. T., & Murphy, M. B.
Published: 2017
Conclusion: There were no adverse events related to marrow aspiration or injection, and this study provides evidence of safety and feasibility of intradiscal BMC therapy. Patient improvement and satisfaction with this surgical alternative supports further study of the therapy
Authors: Navani, A., MD, Ambach, M. A., MD, Navani, R., MS, & Wei, J., DO.
Published: 2018
Conclusion: Intradiscal PRP and BMC injections are promising treatments in patients with discogenic chronic low back and leg pain. When combining proper technique with best known evidence-based practice, this treatment appears to demonstrate good efficacy and safety profile. There are several advantages to the use of autologous biologics: they are readily available, simple to use, cost effective, natural, and potentially healing in nature. While the preliminary results with this therapy have been promising, further well-designed randomized controlled studies are warranted in order to understand the full breadth of its efficacy, risks, applications and complications.
Authors: Centeno, C., Fausel, Z., Stemper, I., Azuike, U., & Dodson, E.
Published: 2020
Conclusion: In conclusion, according to the midterm review data from our randomized controlled, crossover trial, injections of BMC with platelet products provide significant functional gains and reductions in pain compared to a guided home exercise program in the treatment of partial and full-thickness, nonretracted supraspinatus tears. This is the first randomized controlled trial, to our knowledge, of the injection of BMC for the treatment of partial and full-thickness supraspinatus tears in a nonsurgical setting. Our findings suggest that ultrasound-guided injection of BMC and platelet product may be a safe and useful alternative to conservative management nonretracted supraspinatus tendons
